These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19189878)

  • 1. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
    Harvey PD; Pappadopulos E; Lombardo I; Kremer CM
    Schizophr Res; 2009 Nov; 115(1):24-9. PubMed ID: 19189878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
    Hirsch SR; Kissling W; Bäuml J; Power A; O'Connor R
    J Clin Psychiatry; 2002 Jun; 63(6):516-23. PubMed ID: 12088164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
    Schennach R; Riedel M; Spellmann I; Musil R; Obermeier M; Jäger M; Bottlender R; Schmauss M; Laux G; Möller HJ
    Pharmacopsychiatry; 2019 Jul; 52(4):180-185. PubMed ID: 30235496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
    Brook S; Walden J; Benattia I; Siu CO; Romano SJ
    Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
    Potkin SG; Ogasa M; Cucchiaro J; Loebel A
    Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
    Harvey PD; Sacchetti E; Galluzzo A; Romeo F; Gorini B; Bilder RM; Loebel AD
    Schizophr Res; 2008 Oct; 105(1-3):138-43. PubMed ID: 18077136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
    Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
    Citrome L; Yang R; Glue P; Karayal ON
    Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
    van Veelen NM; Grootens KP; Peuskens J; Sabbe BG; Salden ME; Verkes RJ; Kahn RS; Sitskoorn MM
    Schizophr Res; 2010 Jul; 120(1-3):191-8. PubMed ID: 20493663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.